China Coronavirus Vaccine Launches Phase 3 Study in Russia

Petrovax announced on September 21, 2020, it will be able to produce more than 4 million doses of CanSino Biologics's Ad5-nCoV vaccine per month in 2020 at its Moscow Region facilities. And, vaccine production can be increased to 10 million doses per month in 2021 due to the planned expansion of production capacity. As a Russian vaccine manufacturer, Petrovax will have exclusive rights to supply China-based CanSino's vaccine in Russia and the CIS countries.

Additionally, the first group of volunteers participating in an international Phase III clinical trial of the Ad5-nCoV vaccine were vaccinated at Moscow medical centers.

According to clinical regulations, study participants will be under direct supervision for the first 28-days after vaccination and will have to undergo (4) interim face-to-face examinations at treatment centers. According to expert forecasts, during this period, the Ad5-nCoV vaccinated subjects will develop an antibody and cellular immune response to COVID-19.